Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

NCT04724928 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Muscle-Invasive Bladder Carcinoma

Interventions

RADIATION: Metastasis directed therapy (MDT)
DRUG: Immunotherapy
PROCEDURE: Standard of care

Sponsor

University Hospital, Ghent

Collaborators

[object Object]